Efficacy of tadalafil in chronic hypobaric hypoxia-induced pulmonary hypertension: Possible mechanisms

Fundamental and Clinical Pharmacology

Volumn 27, Issue 3, 2013, Pages 271-278

  Rashid, Masrat ^a   Fahim, Mohammad ^b   Kotwani, Anita ^a  

^a UNIVERSITY OF DELHI   (India)

^b HAMDARD UNIVERSITY   (India)

Author keywords

Antioxidant; Hypoxia; Inflammation; Pulmonary hypertension; Tadalafil; Tempol

Indexed keywords

GLUTATHIONE; MALONALDEHYDE; SUPEROXIDE DISMUTASE; TADALAFIL; TEMPOL; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; HYPOBARISM; HYPOXIA; LUNG ARTERY PRESSURE; NONHUMAN; OXIDATIVE STRESS; PNEUMONIA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PULMONARY HYPERTENSION; RAT;

ANIMALS; ANOXIA; ANTI-INFLAMMATORY AGENTS; ANTIOXIDANTS; CARBOLINES; CYCLIC N-OXIDES; DISEASE MODELS, ANIMAL; GLUTATHIONE; HYPERTENSION, PULMONARY; INFLAMMATION; LUNG; MALONDIALDEHYDE; OXIDATIVE STRESS; PHOSPHODIESTERASE 5 INHIBITORS; RATS; RATS, WISTAR; SPIN LABELS; SUPEROXIDE DISMUTASE; TUMOR NECROSIS FACTOR-ALPHA; VENTRICULAR PRESSURE;

EID: 84877799264     PISSN: 07673981     EISSN: 14728206     Source Type: Journal    
DOI: 10.1111/j.1472-8206.2011.01013.x     Document Type: Article

References (34)

1. Prabha N., Hong-fang J., Yue T., Chao-shu T., Jun-bao D.Mechanisms responsible for pulmonary hypertension. Chin. Med. J. (2008) 121 2604-2609.
2. Natalie H., McLoughlin P.The structural basis of pulmonary hypertension in chronic lung disease: remodelling, rarefaction or angiogenesis?J. Anat. (2002) 201 335-348.
3. Falk J.A., Philip K.J., Schwarz E.R.The emergence of oral tadalafil as a once-daily treatment for pulmonary arterial hypertension. Vasc. Health Risk Manag. (2010) 6 273-280.
4. Galie N., Ghofrani H., Torbicki A., Barst R., Rubin L., Badesch D.Sildenafil citrate therapy for pulmonary arterial hypertension. N. Engl. J. Med. (2005) 353 2148-2157.
5. Michelakis E.D., Tymchak W., Lien D., Webster L., Hashimoto K., Archer S.Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: comparison with inhaled nitric oxide. Circulation (2002) 105 2398-2403.
6. Koka S., Kukreja R.C.Attenuation of Doxorubicin-induced cardiotoxicity by tadalafil: a long acting phosphodiesterase-5 inhibitor. Mol. Cell. Pharmacol. (2010) 2 173-178.
7. Erika B.R.Tadalafil for treatment of pulmonary arterial hypertension. Expert Opin. Pharmacother. (2010) 11 127-132.
8. Koka S., Das A., Zhu S.G., Durrant D., Xi L., Kukreja R.C.Long-acting phosphodiesterase-5 inhibitor tadalafil attenuates doxorubicin-induced cardiomyopathy without interfering with chemotherapeutic effect. J. Pharmacol. Exp. Ther. (2010) 334 1023-1030.
9. Arikan D.C., Bakan V., Kurutas E.B., Sayar H., Coskun A.Protective effect of tadalafil on ischemia/reperfusion injury of rat ovary. J.Ped. Surg. (2010) 45 2203-2209.
10. Verit A., Savas M., Ciftci H., Aksoy N., Taskin A., Topal U.Assessment of the acute effects of tadalafil on the cardiovascular system based on examination of serum oxidative status and paraoxonase activity in men with erectile dysfunction: a preliminary study. Int. J. Impot. Res. (2010) 22 115-119.
11. Tsai B.M., Turrentine M.W., Sheridan B.C. et al.Differential effects of phosphodiesterase-5 inhibitors on hypoxic pulmonary vasoconstriction and pulmonary artery cytokine expression. Ann. Thorac. Surg. (2006) 81 272-278.
12. Chandel N.S., Trzyna W.C., McClintock D.S., Schumacker P.T.Role of oxidants in NF-kappa B activation and TNF-alpha gene transcription induced by hypoxia and endotoxin. J. Immunol. (2000) 165 1013-1021.
13. Elmedal B., deDam M.Y., Mulvany M.J., Siminsen U.The superoxide dismutase mimetic, tempol, blunts right ventricular hypertrophy in chronic hypoxic rats. Br. J. Pharmacol. (2004) 141 105-113.
14. Thomas B.H., Wanstall J.C.Alterations in pulmonary vascular function in rats exposed to intermittent hypoxia. Eur. J. Pharmacol. (2003) 477 153-161.
15. Wright J.R., Colby H.D., Miles P.R.Cytosolic factors that affect microsomal lipid peroxidation in lung and liver. Arch. Biochem. Biophys. (1981) 206 296-304.
16. Jollow D., Mitchell L., Zampaglione N., Gillete J.Bromobenzene induced liver necrosis: protective role of glutathione an evidence for 3, 4 bromo benzenoxide as the hepatotoxic intermediate. Pharmacology (1974) 11 151-169.
17. Voelkel N.F., Rubin M.T.Hypoxia-induced pulmonary vascular remodelling: a model for what human disease?J. Clin. Invest. (2000) 106 733-738.
18. Andersen C.U., Mulvany M.J., Simonsen U.Lack of synergistic effect of molsidomine and sildenafil on development of pulmonary hypertension in chronic hypoxic rats. Eur. J. Pharmacol. (2005) 510 87-96.
19. Tay E.L., Geok-Mui M.K., Poh-Hoon M.C., Yip J.Sustained benefit of tadalafil in patients with pulmonary arterial hypertension with prior response to sildenafil: a case series of 12 patients. Int. J. Cardiol. (2008) 125 416-417.
20. Affuso F., Palmieri E.A., Di Conza P., Guardasole V., Fazio S.Tadalafil improves quality of life and exercise tolerance in idiopathic pulmonary arterial hypertension. Int. J. Cardiol. (2006) 108 429-431.
21. Waypa G.B., Chandel N.S., Schumacker P.T.Model for hypoxic pulmonary vasoconstriction involving mitochondrial oxygen sensing. Circ. Res. (2001) 88 1259-1266.
22. Cracowski J.L., Cracowski C., Bessard G. et al.Increased lipid peroxidation in patients with pulmonary hypertension. Am. J. Respir. Crit. Care Med. (2001) 164 1038-1042.
23. Langleben D., Fox R.B., Jones R.C., Reid L.M.Effects of dimethylthiourea on chronic hypoxia-induced pulmonary arterial remodelling and ventricular hypertrophy in rats. Clin. Invest. Med. (1989) 12 235-240.
24. Rosen R.C., Kostis J.B.Overview of phosphodiesterase 5 inhibition in erectile dysfunction. Am. J. Cardiol. (2003) 92 9M-18M.
25. Savas M., Yeni E., Verit A. et al.Acute effect of phosphodiesterase type 5 inhibitor on serum oxidative status and prolidase activities in men with erectile dysfunction. Clinics (2010) 65 1311-1314.
26. Savale L., Tu L., Rideau D. et al.Impact of interleukin-6 on hypoxia-induced pulmonary hypertension and lung inflammation in mice. Resp. Res. (2009) 10 6.
27. Sheridan B.C., McIntyre R.C., Meldrum D.R., Meng X., Fullerton D.A.Endotoxin stuns cGMP-mediated pulmonary vasorelaxation. Shock (1997) 8 207-212.
28. McIntyre R.C., Pulido E.J. Jr, Sheridan B.Endotoxin differentially impairs receptor-mediated relaxation in rat isolated pulmonary and thoracic aortic vessels. J. Trauma (1998) 45 862-867.
29. Tamura D.Y., Moore E.E., Partrick D.A.Acute hypoxemia in humans enhances the neutrophil inflammatory response. Shock (2002) 17 269-273.
30. Kisala J.M., Ayala A., Stephan R.N., Chuadry I.H.A model of pulmonary atelectasis in rats: activation of alveolar macrophage and cytokine release. Am. J. Physiol. (1993) 264 R610-R614.
31. Johnson A., Ferro T.J.TNF-alpha augments pulmonary vasoconstriction via the inhibition of nitrovasodilator activity. J. Appl. Physiol. (1992) 73 2483-2492.
32. Castaneda J., Isusi A., Tamayo L.Hypoxic pulmonary vasoconstriction increases during endotoxemia in the perfused rat lung. J. Trauma (2001) 50 882-886.
33. Liu S.F., Dewar A., Crawley D.E., Barnes P.J., Evans T.W.Effect of tumor necrosis factor on hypoxic pulmonary vasoconstriction. J. Appl. Physiol. (1992) 72 1044-1049.
34. Tuder R.M., Voelkel N.F.Pulmonary hypertension and inflammation. J. Lab. Clin. Med. (1998) 132 16-24.